AGFAGDDAPR is a bioactive peptide that is a competitive and orally effective inhibitor of dipeptidyl peptidase-IV (DPP-IV). AGFAGDDAPR can enhance the level of GLP-1 in the body by inhibiting DPP-IV, thereby stimulating insulin secretion, improving beta-cell function, and inhibiting abnormal proliferation of alpha-cells, exerting anti-diabetic effects. AGFAGDDAPR can be used for research on type 2 diabetes[1].
Molekulargewicht:
976.00
Reinheit:
98.01
CAS Nummer:
[330204-04-1]
Formel:
C41H61N13O15
Target-Kategorie:
Dipeptidyl Peptidase,GLP Receptor
Anwendungsbeschreibung:
MCE Product type: Peptides
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten